Hinge Health Inc. Class A Common Stock vs Intel Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Intel Corp trades at $95.38 (market cap $543.46B). The key difference: Intel Corp is far larger — about 64.1× Hinge Health Inc. Class A Common Stock's market cap, and Intel Corp pays a 2.24% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Intel Corp for 116 Days on average.
| HNGE | INTC | |
|---|---|---|
Market Cap | $8.48B | $543.46B |
Volume | 879,799 | 87,420,405 |
Sector | Health | Technology |
52-Week High | $105.14 | $140.94 |
52-Week Low | $31.17 | $33.62 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $8.10B | $564.27B |
Dividend Yield | — | 2.24% |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Intel (INTC) trades at $98.12, down 3.19% today, amid mixed technical signals with bearish moving averages but bullish oscillators. Fundamentally, the company shows improving operational trends with three consecutive quarterly EPS beats and positive operating cash flow of $9.70B in 2025, though net income remains negative at -$267M. The stock has surged over 220% year-to-date as investors assess the progress of Intel's foundry turnaround strategy and High-NA chipmaking advancements.
Intel presents a high-risk, high-reward opportunity as the company executes its strategic pivot to a foundry model. While valuation metrics appear stretched with a P/E of 904, analyst consensus targets $111.72 suggesting 14% upside potential. Key risks include intense competition from TSMC and AMD, ongoing negative profitability, and the execution challenges of the foundry transition in a capital-intensive industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →